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Superﬁcial venous surgery and perforator vein surgery, speciﬁcally, have a long and varied history in the evolution of
vascular surgery, especially because venous disease continues to be extremely common. As with other areas of our specialty,
perforator vein procedures have progressed from being purely open operations to becoming less invasive procedures.
Despite this, there remainsmuch discussion (as well as overt disagreement) aboutwhether perforator vein surgery is actually
appropriate and beneﬁcial in the ﬁrst place. Surgeons have no level I evidence from randomized controlled studies to
determine whether perforator vein surgery does or does not reduce the chances of recurrence of superﬁcial venous vari-
cosities, so we must rely on the evidence as it currently is. Perhaps not surprisingly, our two experts have assembled
divergent opinions on the role of perforator venous surgery in contemporary practice. (J Vasc Surg 2014;60:796-803.)PART I: VENOUS PERFORATOR SURGERY IS
PROVEN AND DOES REDUCE RECURRENCES
Mark S. Whiteley, MD, Guildford, United Kingdom
There are few areas of superﬁcial venous surgery inwhich
opinions are as polarized as that regarding the role of perfo-
rator veins and incompetent perforator veins (IPVs) in the
treatment of varicose veins. On one side, perforating veins
are regarded as “normal,” allowing blood reﬂuxing in
incompetent superﬁcial venous trunks to re-enter the sys-
tem, and thus, they should be left alone,1 regardless of their
size or apparent reﬂux on certain tests. On the other side,
IPVs are seen as different from competent perforating veins,
allowing signiﬁcant venous outﬂow from the deep system
into the superﬁcial venous system and causing morphic
changes to the local superﬁcial veins (varicosities or telangi-
ectasia) or tissue (edema or fascia cutaneous changes).2
The large number of publications on the subject do not
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://dx.doi.org/10.1016/j.jvs.2014.06.102However, as practicing clinicians, we are not able to post-
pone the management of patients presenting with varicose
veins or other sequelae of superﬁcial venous reﬂux disease
until the case has been proven beyond doubt.
As such, practicing clinicians need to approach this sub-
ject in a pragmatic fashion. We need to treat our patients in
accordance with our own observations and experience and
be guided by what evidence is currently available. The
absence of a deﬁnitive randomized controlled trial (RCT)
does not mean that the science is unprovendmerely that
the level of evidence is lower than some might like. A great
many procedures are performed daily in our hospitals that
have the same or even lower levels of evidence to support
them. Merely listing the current publications and available
research into IPVs and varicose veins is not sufﬁcient to
answer this question satisfactorily because we may end up
denying our patients the excellent results that have been re-
ported when perforator veins are treated in conjunction
with the treatment of truncal venous reﬂux.3
Before launching into the debate proper, we must
acknowledge the difﬁculty in producing a standard deﬁni-
tion of what is a signiﬁcant IPV.
DIAGNOSIS OF AN IPV
Although most clinicians would accept that a perfo-
rating vein is a venous communication between the super-
ﬁcial and deep veins in the leg, “perforating” through the
deep investing fascia and, hence, the underlying muscle,
the question about what constitutes incompetence and
what level of reﬂux in IPVs is signiﬁcant, is not exact.
For those who believe that bidirectional ﬂow in perfo-
rators is abnormal, many use the diameter of the perforator
as a marker of incompetence. However, although
>3.9 mm in the subfascial portion indicates reﬂux, one-
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cannot use size alone to diagnose an IPV.4 Agreements of
pathologic reﬂux times also vary, with times for reﬂux in
IPVs of >350 ms being proposed rather than the more
commonly used >500 ms.5
THE ASSOCIATION BETWEEN IPVS AND
VARICOSE VEINSDPRIMARY AND
RECURRENT VARICOSE VEINS
Although the deﬁnition of what constitutes an IPV is not
exact, many IPVs are clearly reﬂuxing, and so many associa-
tions have been identiﬁed between clearly reﬂuxing IPVs and
varicose veins. There is a clear association between the pres-
ence of IPV and some varicose veins,6,7 with increasing
numbers and sizes of IPVs in progressively worsening vari-
cose veins6 and increased numbers of IPVs found in legs
with recurrent varicose veins.7 These and other studies
show the association between varicose veins and IPVs both
above-knee and below-knee. To date, there has not been a
clear attempt to separate the above-knee and below-knee
IPVs into distinct pathophysiologic entities, and so argu-
ments must not be confused by separating them at this time.
None of these studies have been able to show a causa-
tive relationship between IPVs and varicose veins, because
when the IPVs reﬂux blood from the deep system, there is
almost always a corruption of valves in a local superﬁcial
venous trunk. Hence, when reﬂux is found in an IPV and
also in an associated section of truncal vein, there is no clear
way of telling which was cause and which was effect.6
However, these studies, coupled with clinical observa-
tions of the occasional patients who present with varicose
veins arising only from IPVs and improve when these
have been treated successfully, have led many clinicians,
such as myself, to treat IPV when they are identiﬁed. So
to return to the question posed, is this venous perforator
surgery unproven?
IS VENOUS PERFORATOR VEIN SURGERY
UNPROVEN?
If we accept that it is the venous reﬂux in the IPV that
signiﬁes venous pathology and distinguishes an IPV from a
normal perforating vein, then the success of perforator vein
surgery can be measured by the successful closure or pre-
vention of reﬂux in these veins. To use more global deﬁni-
tions of success, such as patient-reported outcomes, which
has become fashionable in venous surgery, hides the effects
of treating or failing to treat an IPV by including con-
founding variables, such as the treatment of truncal reﬂux
or phlebectomy, which may or may not be associated
with the IPV in question.
Studies in the past have suggested that treating truncal
reﬂux in the great saphenous vein (GSV) will allow an IPV
to shrink and become competent again.8,9 Our own study,
however, showed this was not the case when the IPVs were
followed up over a long enough period, suggesting the pre-
vious observations had mistaken acute changes for perma-
nent restoration of function.10 Such acute changes mightbe explained by temporary occlusion of the IPV by postop-
erative thrombophlebitis.
Hence, to permanently stop venous reﬂux in IPVs in
patients with varicose veins, the IPV itself needs to be
treated. Before 1985, the only way to do this was ligation
by open surgery, as in the Linton operation11 or the Dodd
and Cockett procedure,12 or by blind disruption such as
that proposed by Edwards.13 In 1985, however, Hauer14
invented subfascial endoscopic perforating vein surgery
(SEPS), allowing an endoscope to be placed in the subfas-
cial space and the IPV to be visualized and clipped, with or
without subsequent division.15 Studies on the efﬁcacy of
SEPS to stop reﬂux in IPVs have shown a midterm tech-
nical success rate of 78%.16
With the advent of catheter-based endovenous proce-
dures, we invented the transluminal occlusion of perforator
(TRLOP) technique in 2001, presented it in 2002,17 and
published it in 2004.18 TRLOP describes the method of
percutaneous cannulation of an IPV under ultrasound guid-
ance through a single needle hole, so that any treatment cath-
eter can be passed into it for thermal or nonthermal ablation.
The success of TRLOP at 1 and 5 years was the same or better
than that reported for SEPS19,20 and encouraged other au-
thors to “reinvent” and to attempt to rename the TRLOP
technique. Since the original descriptions of TRLOP in
2002 and 2004, terms, such as percutaneous ablation of per-
forators,21 ultrasound-guided percutaneous ablation,22 and
other descriptive terms or device names have appeared,23
although none have added anything to the original descrip-
tion of the TRLOP technique as presented in 2002 and 2004.
Nevertheless, whatever a clinician might erroneously
call his or her version of the TRLOP technique, the ability
to close the IPV to prevent venous reﬂux in>80% in the long-
term has now been proved. As such, we can clearly conclude
that to state that “perforator vein surgery is unproven” is
clearly wrong. Now we can turn our attention to the second
part of the questiondthat of reduction of recurrences.PERFORATOR VEIN SURGERY . DOES NOT
REDUCE RECURRENCES?
That perforator vein surgery reduces the recurrence of
venous leg ulcers is well proven by individual studies24-26
and also by a meta-analysis of the available literature.27
Indeed, O’Donnell himself has been involved in such
work,“These ﬁndings emphasize the importance of ligating
all incompetent perforating veins, as ulcer healing was
never achieved when residual perforating veins were found
at follow-up.”28 Although some might try to argue that it
is deep vein reﬂux in such patients rather than the IPVs that
is important, O’Donnell et al29 were able to reassure us
that “deep system reﬂux as measured with duplex scan
valve closure times did not correlate with the rate of ulcer
healing or recurrence,” whereas the treatment of IPVs
was of clear beneﬁt. Hence, the treatment of IPVs in
venous ulceration is proved to reduce ulcer recurrence.
However, when the same venous reﬂux is found in the
same IPV but in a leg with varicose veins rather than leg
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CONCLUSIONS
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ping venous reﬂux in IPV. The reduction of recurrent
venous ulceration after treatment of IPV has been proven
beyond doubt, and so, unless the sceptics can show a
different mechanism of action between venous reﬂux in
IPVs in the legs with venous ulceration compared with
the venous reﬂux in IPVs in legs with varicose veins,
then these results can be extrapolated to the treatment
of varicose veins.
Although treatment of IPVs has not yet been proven
to reduce recurrences, the circumstantial evidence is
overwhelming. The studies presented here show that
IPVs are associated with varicose veins and that as vari-
cose veins worsen, the numbers of and sizes of IPVs
increase. Furthermore, recurrent varicose veins are associ-
ated with increased numbers of IPVs, suggesting a caus-
ative link. Studies looking at the causes of recurrent
varicose veins after open surgery regularly conﬁrm IPVsare a major cause of recurrence, and IPVs have been
shown to be the major cause of recurrent varicose veins
after endovenous surgery.
Until irrefutable evidence has been produced to the
satisfaction of all, the onus is on physicians who support
the contention under debate to prove that treating IPVs
does not reduce recurrences in view of the overwhelming
circumstantial evidence available to the contrary.
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UNPROVEN AND DOES NOT REDUCE
RECURRENCES
Thomas F. O’Donnell, MD, Boston, Mass
My position in this debate is that treatment of incom-
petent perforating veins (IPVs) in association with ablation
of the great saphenous vein (GSV) for axial reﬂux does not
reduce recurrent varices after surgery (REVAS). This
debate focuses on IPV treatment as an indication to pre-
vent REVAS, not as an indication to promote venous ulcer
healing or prevent recurrence, where the argument may be
quite different. The argument to not treat IPVs perempto-
rily at the time of GSV surgery, as a method to prevent
recurrence after GSV surgery, is based on:1. IPVs are not the major cause of REVAS.
2. The treatment of GSV reﬂux alone will concomi-
tantly correct a signiﬁcant proportion of IPVs.
3. The interruption of IPVs with many techniques is
associated with residual or “missed IPVs,” and the
procedure is not permanent or durable, leading to
true REVAS of the IPVs.
4. Recurrence is frequently related to progression of
chronic venous insufﬁciency, which is not prevented
bypreemptory IPVablation at the timeofGSVablation.OVERVIEW
Perrin et al1 led a consensus conference in 1998, which
brought both deﬁnition and classiﬁcation to the problem of
REVASdmuch like the CEAP classiﬁcation did for the
larger area of chronic venous insufﬁciency.2 REVAS was
deﬁned as “the existence of varicose veins in a lower limb
previously operated on for varicose veins with or without
adjuvant therapies.” REVAS was classiﬁed by:
1. Topographic sites, such as the thigh;
2. Source of recurrence (the cause of deep venous reﬂux
into the superﬁcial system), such as the perforators in
the thigh or calf; and
3. The nature of the sources, whether the recurrence was
at the site of previous surgery or at another new site.
REVAS is customarily divided into anatomic recur-
rence, which is deﬁned by duplex ultrasound imaging and
may be asymptomatic; and clinical recurrence, which is
associated with symptomatic recurrent varicosities. Finally,
whether the patient underwent treatment of REVAS can
be viewed as a patient outcome measure.
IPVs ARE NOT THE MAJOR CAUSE OF REVAS
During the last decade, endovenous ablation (EVA) of
the GSV or small saphenous veins (SSVs) by laser ablation
(EVLA) or radiofrequency ablation (RFA) has become the
principle therapy for varicose veins in the United States rather
than ligation and stripping (L&S), and as a result, EVA has
increased 450-fold during the last decade.3 EVAhas been rec-
ommended as the primary procedure for saphenous incompe-
tence by the Society for Vascular Surgery/American Venous
Forum Guidelines for varicose veins4 and by the United
Kingdom National Institute for Health and Clinical Excel-
lence Guidelines.5 Thus, REVAS associated with EVA be-
comes an important consideration. L& S of the GSV by the
short strip technique usually avoids treatment of the below-
knee GSV,6 whereas EVA may access the below-knee GSV
and ablate the upper portion of the below-knee GSV.3
REVAS has been well studied after L&S. In a multi-
center study from eight countries involving 199 patients
with REVAS after L&S, Perrin et al7 showed that the
commonest sites of recurrence were the thigh (68%)
and the lower leg (85%). By contrast, that study showed
the saphenofemoral region (47%) and thigh perforators
(30%) were the major sources of REVAS. The lower leg
Table I. The effect of great saphenous vein (GSV)
treatment by ligation and stripping (L&S) on
incompetent perforating veins (IPVs)
First author Year
Limbs,
No.
Exam
time,
weeks
IPVs, No. (%)
Pre-op Post-op New
Stuart12 1998 62 14 40 (65) 23 (37)
Mendes13 2003 24 12 24 (100) 8 (33)
Blomgren14 2005 103 8 42 (100) 23 (45) 8 (18)
Gohel15 2005 115 59 (52) 44 (43) 12 (12)
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fortunately, no information was given about the number
of limbs that had speciﬁc treatment of IPVs at the time
of the initial L&S.
Using the REVAS classiﬁcation system, Bush et al8
reported on REVAS from seven centers treating 2380
patients, of which a strikingly low 164 (7%) developed
REVAS at a median of 3 years.8 EVLA was performed
as the initial procedure in 80% of patients, whereas the
older RFA catheter was used in most of the RFA proce-
dures. No information was provided on whether IPVs
were treated with the original ablation. The authors
used the all-encompassing term of “perforators” for the
source of reﬂux. When the speciﬁc anatomic site was
deﬁned, perforators in the thigh, rather than in the calf,
were associated with a statistical increase in GSV recanali-
zation. In their analysis, REVAS appears to be deﬁned as
reﬂux on duplex imaging, and the incidence of clinical
REVAS is difﬁcult to tease out. Of interest to this debate,
REVAS developed at new previously nonreﬂuxing
sitesd16% at the SSV and 24% at the anterior accessory
(AA) GSV. Thus, 40% of all REVAS was due to disease
progression and not amenable to preemptory treatment
of the IPVs at the time of EVA.
The least biased information and of highest evidentiary
value about REVAS after EVA can be derived from ran-
domized controlled trials (RCTs), where the data are
collected prospectively through a uniform protocol, partic-
ularly with duplex ultrasound follow-up and preferably us-
ing the REVAS classiﬁcation.3 Those RCTs where no
speciﬁc treatment was provided to the IPVs were exam-
ined. In an earlier and smaller RCT, Perala et al9 described
their ﬁndings at 3 years after RFA in 15 patients. The cause
of REVAS, which occurred in 33% of their patients, was
reﬂux in an AASV or in a patent duplicate GSV. No
IPVs were detected.
Rasmussen et al10 compared EVLA (67 limbs in 60 pa-
tients) with L&S (67 limbs in 58 patients) in a RCT over a
5-year period. The varicosities of the patients in this RCT
were treated with stab phlebectomies for EVA and L&S,
but no speciﬁc treatment was directed at IPVs. At 5 years,
there was no difference in clinical REVAS between EVLA
(47%) and L&S (55%), but retreatment principally by
sclerotherapy was required in a lesser proportion (39%).
Reﬂux was found in the AASV in 24% of the limbs and
in the thigh perforators in another 20%, but calf IPVs
accounted for only 16%. Disselhoff et al11 compared
EVLA vs L&S in 120 patients, and at 2 years, calf IPVs
were not described as a cause of REVAS.THE TREATMENT OF GSV REFLUX ALONE
WILL CONCOMITANTLY CORRECT A
SIGNIFICANT PROPORTION OF IPVS
Stuart et al12 were one of the ﬁrst groups to demon-
strate a reduction in the number of duplex-detected
IPVs after L&S of the GSV from 65% of limbs preopera-
tively to 37% postoperatively (P < .01), whereas theproportion of IPVs declined from 52% to 28%. They
found, however, that deep venous incompetence
adversely affected the reduction in IPVs with L&S.
Table I reports a similar signiﬁcant decrease in the propor-
tion of limbs with IPVs after L&S in several other series of
predominantly CEAP C2-3 patients.
13,14 The Gohel
et al15 study of duplex follow-up of the Effect of Surgery
and Compression on Healing and Recurrence (ESCHAR)
RCT, where all patients were C5-6 and many had deep
venous incompetence, found a smaller but signiﬁcant
decrease in postoperative IPVs. In these combined series,
the average decrease in of IPVs after treatment of the GSV
postoperatively was 50%.
THE INTERRUPTION OF IPVs WITH MANY
TECHNIQUES IS ASSOCIATED NOT ONLY
WITH RESIDUAL OR MISSED IPVs, BUT ALSO
THIS PROCEDURE IS NOT PERMANENT OR
DURABLE, LEADING TO TRUE REVAS OF IPVs.
To advocate a procedure that is preventative, the tech-
nique must have a high initial success rate and the proce-
dure must be effective long enough to garner the
proposed late beneﬁts against REVAS. The current treat-
ment of IPVs has evolved from the open procedures of Lin-
ton16 and Cockett,17 where all perforating veins were
visualized and ligated by using a long medial subfascial inci-
sion, through SEPS, where the IPVs were selectively abla-
ted by an endoscopic approach,18,19 to the current
technique of direct percutaneous thermal or sclerotherapy
treatment of the IPVs under ultrasound guidance.20
Our own experience showed an early ultrasound resid-
ual or “missed IPV” rate of 22% in 19 limbs after SEPS,21
which is similar to the residual rate of 20% described by
Sybrandy et al22 in their 40-patient RCT, which compared
SEPS with the Linton procedure (0% residual rate). On
follow-up duplex examination, the large 200-limb Dutch
SEPS RCT revealed at least one residual/missed IPV in
50% of the procedures.23 As the former trial suggests,
SEPS is highly operator dependent, and this is underscored
by the Kolvenbach et al24 redo SEPS series of 19 patients,
which was principally referral-based, presumably from
lower-volume centers. Besides technical problems with re-
sidual IPVs, progression of a perforator, which was normal
on the initial duplex assessment, to an IPV frequently oc-
curs. In the REVAS classiﬁcation, this has been deﬁned
Table II. Comparison of the occlusion/residual rate
with direct percutaneous ablation of perforators to
residual incompetent perforating veins (IPVs) after
subfascial endoscopic perforator vein surgery (SEPS)
First author Year
Limbs,
No.
Perfs,
No.
F/U,
months
Occluded/
residual, %
RFA
Chang26 2005 38 6 63/37
Lumsden27 2006 55 97 12 44/56
Elias28 2007 . 20 0.75 81/19
van den Bos29 2009 12 14 0.25 100/0
Bacon30 2009 58 125 60 66/34
Hingorani31 2009 38 48 1 88/12
Lawrence32 2011 51 86 . 58/42a
24 79/29
Laser
Proebstle33 2007 60 67 3 99/1
Kabnick34 2006 . 25 4 85/15
Elias28 2007 . 50 . 90/10
Murphy35 2006 . 100 . 90/10
Sclerotherapy
Masuda36 2006 80 . 98/2a
20 75
Kiguchi37 2014 62 189 36 54/46
SEPS
Iafrati21 1997 15 18 5.5 22
Roka25 2006 92 0.25 100
Sybrandy22 2001 20 . 1.5 28
Linton16 2001 19 . . 0
F/U, Follow-up; RFA, radiofrequency ablation.
aFirst row of data indicates the initial ﬁndings.
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0% residual IPV rate with the Linton procedure had
climbed to a 45% new REVAS rate in later follow-up,
whereas after SEPS, this ﬁgure had doubled to a 42%
new REVAS rate. After SEPS in 92 limbs, no residual
IPVs were observed on duplex in the Roka et al25 series,
but new REVAS of IPVs developed in 20 limbs (20%) dur-
ing a mean follow-up of 3.7 years.
The current techniques of thermal ablation of IPVs,
such as transluminal occlusion of perforator veins
(TRLOP) or percutaneous ablation of perforators
(PAPS), is hampered by considerable operator variability
with a steep learning curve.20 Table II summarizes the inci-
dence of residual IPVs after PAPS in the published litera-
ture as well as from series presented at meetings. The
rate of IPV occlusion after RFA-PAPS varies from two se-
ries at 60% (40% residual REVAS rate)26,27 to several at
$90%.28,29,31 Laser-PAPS appeared to have somewhat bet-
ter early occlusion rates.33-35 The appreciable learning
curve of PAPS is best appreciated from the large experience
of Lawrence et al,32 where the initial success rate with
RFA-PAPS was 58% and rose to 79% after 2 years of
experience.
Strong further evidence on the lack of permanence of
IPV treatment (true REVAS) is provided by the large
prospective study of van Rij et al,38 who monitored 145
limbs with 850 IPVs, which were directly ligated underduplex ultrasound guidance. To distinguish between re-
sidual IPVs and new IPVs causing REVAS, the limbs
were topographically mapped at the initial treatment for
subsequent serial postoperative duplex examinations. At
3 years, they observed that 76% of limbs had developed
380 further IPVs. Of these, 152 (40%) recurred at the
site of the IPV ligation due to neovascularizationdsame
site REVAS; most importantly, 225 (59%) previously
normal perforators by duplex examination increased their
diameter and became incompetent over the follow-up
perioddnew REVAS, which is indicative of disease pro-
gression. The sole series of direct thermal ablation of
IPVs with long-term data comes from my debate oppo-
nent’s unit.30 The authors described the results of an
audit of 82 of the 106 initially treated patients (25 were
excluded due to distance). Sixty-seven patients
responded, of whom 37 agreed to participate (35% of
the original cohort and 55% of the respondents). Of the
125 IPVs originally treated, 81% were closed (21%
open) in 20 limbs (34% of limbs), and 24% of the limbs
demonstrated new IPVs.
Kiguchi et al37 and associates treated 62 C6 patients
with repeated sclerotherapy under duplex guidance and
found a low 54% had occluded at a mean of 30.2 months.
Finally, the case series by Masuda et al36 illustrates the
recurrence of incompetence in IPVs after ultrasound-
guided liquid sclerotherapy of IPVs in 80 limbs (C2-4 in
70%). Although 98% of the IPVs were occluded initially
on duplex ultrasound, only 75% remain occluded at 1½
years.RECURRENCE OVER TIME IS RELATED TO
PROGRESSION OF CHRONIC VENOUS
INSUFFICIENCY
Disease progression has been deﬁned as a result of the
natural history and evolution of the disease, where the
involved varicosities are not dilated and varicose at the
time of the initial treatment but develop reﬂux due to
the “natural history of the disease process.”39 Van Rij
et al40 monitored 92 patients with 127 limbs that under-
went L&S of the GSV with concomitant duplex
ultrasound-guided direct ligation of signiﬁcant IPVs. Serial
duplex and air plethysmography studies of these patients
showed 13.7% had clinical evidence of recurrence at
3 months, and this ﬁgure jumped to 51.7% at 3 years.
The venous ﬁlling index, a measure of reﬂux, progressively
increased in a great proportion of limbs during the follow-
up period. This indicated a physiologic recurrence that par-
alleled and preceded clinical recurrence. Despite ligation of
all signiﬁcant IPVs at the initial surgery, new IPVs rose to
59% and 90% of limbs at 2 and 3 years, respectively, which
is indicative of the major role of disease progression in
REVAS. The previously quoted Recurrent Veins After
Thermal Ablation (REVATA) study of Bush et al8 found
that that 40% of all REVAS was due to disease progression
in new sitesd16% at the SSV and 24% at the AAGSVdthat
were all previously normal.8
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One can only conclude that preemptive treatment of
IPVs at the time of GSV surgery is not associated with pre-
vention of recurrence. The best strategy for treatment of
recurrent varicose veins after GSV ablation and removal
of varicosities may be similar to that used for arterial occlu-
sive disease or dental carries, with periodic check-ups and
treatment as the problem arises.REFERENCES
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United KingdomIn the midst of this spirited discussion there is one issue where
our debaters agree, namely the role of incompetent perforator vein
(IPV) interruption in promoting venous ulcer healing or prevent-
ing recurrence. This is consistent with the Practice Guidelines of
the Society for Vascular Surgery and the American Venous Forum
that recommends “treatment of pathologic perforating veins that
includes those with outward ﬂow $500-ms duration, with a diam-
eter $3.5 mm, located beneath healed or open venous ulcer (class
C5-C6).”
1 This same document, however, does not recommend
treatment of IPVs in patients with simple varicose veins (class
C2), based on a “moderate” level of evidence. This area of conten-
tion has prompted this discussion by our experts and it is evident
that there are several areas of disagreement.
In his argument in favor of interruption of IPVs to reduce
varicose vein recurrence, Prof Whitely outlines the literature
describing an association between IPVs and varicose veins but
readily admits that a causal relationship has not been deﬁnitely
proved, as is the case with venous ulcerations. He proposes a com-
mon pathophysiology and shared role of IPVs between venous ul-
cers and varicose veins that, he argues, would validate IPV surgery
with varicose veins as it does with venous ulcers. Interruption of
IPVs is possible with a high degree of success (>80%) with increas-
ingly less invasive techniques including those pioneered by Profes-
sor Whitely, but is it necessary? He argues that it is necessary and is
supported by “overwhelming circumstantial evidence.”Dr O’Donnell counters with the argument that venous stasis
ulcers and varicose veins do not share a common pathophysiology
and that IPVs are not the major cause of recurrent varicosities,
which are a result of the natural history of the disease itself, irre-
spective of IPV status. Regardless, he argues, IPV surgery is not
as successful as its proponents claim, with missed veins and less-
than-optimal durability.
This leaves us without a deﬁnitive answer. The role for perfo-
rator vein surgery in advanced venous disease, or venous ulcers,
seems clear, but remains less so with lesser degrees of disease or
varicose veins. Although IPV surgery can be done with some suc-
cess by less invasive techniques, the question remains about
whether it has any value in decreasing the risk of recurrent varicos-
ities. The current level of evidence does not support its routine use
in C2 disease and we should await further evidence before recom-
mending its wider adoption.REFERENCE
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